Bedrijf laden
Just reported
Q3 2026 results
From Labcorp's results release of 28 oktober 2026; its quarterly report has since been filed.
Revenue
Actual
US$ 3,81B
+6,9% y/y
+2,1% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$ 3,22
+3,2% y/y
-12% q/qGuided
—
No guide given
Operating income, GAAP
Actual
US$ 402,1M
+1,4% y/y
-11% q/qGuided
—
No guide given
Company outlook
Full year 2026
- EPS, adjustedUS$ 18,30 – US$ 18,70Raised +1,0%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Labcorp is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Diagnostics and Research
Graded A or B and worth $2B or more: A first, then the largest.
TMOThermo Fisher Scientific Inc.US$ 259,4BA+
IDXXIdexx Laboratories Inc.US$ 55,5BA+
IQVIQVIA Holdings Inc.US$ 43,7BA
ILMNIllumina, Inc.US$ 31,3BA+
DGXQuest Diagnostics IncUS$ 28,6BA
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 okt 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 okt 2026CAGraded C, now A
Hoe het geld verdient
- Diagnostic laboratory testing78%
- Biopharma laboratory services22%
De omzetaandelen zijn schattingen voor year ended 2025-12-31, geen cijfers uit een ingediend rapport.
Concurreert met
Wat het verkoopt6
Routine and specialty diagnostic tests
Laboratory tests on patient samples, including tests used to diagnose and monitor diseases, as well as occupational, wellness and forensic deoxyribonucleic acid (DNA) testing.
ColoSense
A stool-based colorectal cancer screening test that people collect at home; it is approved by the U.S. Food and Drug Administration (FDA).
PlasmaDetect genome minimal residual disease (MRD)
A blood test being evaluated for monitoring whether early-stage lung cancer returns after treatment.
Nog 3 tonen
Labcorp OnDemand
A service through which consumers can order certain health and wellness tests directly, including tests for cancer screening, allergies and men's and women's health.
Central laboratory services
Laboratory testing for pharmaceutical and biotechnology companies conducting clinical studies of medicines.
Early development laboratory services
Laboratory services supporting early stages of drug research and development.
Wie het koopt6
- Physicians and medical practices order tests for patients and may receive the bills themselves or direct billing to patients or health plans.
- Hospitals and health systems use Labcorp for testing, including outreach laboratory services and tests they send to an outside laboratory.
- Health plans and managed care organizations pay for covered tests under negotiated fee schedules or per-member payment arrangements.
Nog 3 tonen
- Medicare and Medicaid pay for eligible tests under government fee schedules.
- Patients pay for tests when uninsured, for their share of an insured test, or when they order tests directly.
- Pharmaceutical, biotechnology, medical device and diagnostic companies, along with contract research organizations, buy laboratory services under contracts.
Waar het op steunt, en wat het kan breken
Waar het bedrijf van afhangt
- 1Diagnostic revenue depends on reimbursement rules, coverage decisions and negotiated payment rates from health plans and government programs.
- 2A portion of diagnostic revenue depends on collecting patient balances, including deductibles, coinsurance and bills for uninsured patients.
- 3Biopharma Laboratory Services depends in part on research and development spending by pharmaceutical, biotechnology and medical device companies.
- 4Laboratory work depends on qualified staff, laboratory facilities, supplies and third-party transportation and services.
Wat er mis kan gaan
- 1Changes to government or health-plan coverage and reimbursement, including changes affecting Medicaid or insurance exchanges, could reduce testing volumes or payments. The company has identified possible changes to Medicaid and the Affordable Care Act as a source of potential pressure on diagnostic testing.
- 2Patients account for a material portion of diagnostic receivables, and Labcorp may collect less than billed when patients cannot or will not pay their share.
- 3Reduced research and development spending, changes in pharmaceutical or medical-device regulation, or the loss or early termination of contracts could reduce demand for Biopharma Laboratory Services or leave Labcorp with contract costs it cannot recover.
Over Labcorp Holdings Inc.
Labcorp tests patient samples at its laboratories, performing routine and specialty tests for diagnosing and monitoring health conditions. Its Biopharma Laboratory Services business performs laboratory work for pharmaceutical, biotechnology, medical device and diagnostic companies, including central laboratory testing and early development services. Patients can also order some tests directly through Labcorp OnDemand.
- Hoofdkantoor
- Burlington, North Carolina
- Opgericht in
- 1978
- Genoteerd aan
- NYSE
- Einde boekjaar
- December 31
Gebouwd uit de eigen deponeringen van Labcorp Holdings Inc. bij de Amerikaanse toezichthouder Securities and Exchange Commission (SEC). De cijfers zijn zoals gerapporteerd, met de historie per aandeel herrekend naar de huidige aandelenbasis. Dit beschrijft een bedrijf — het is geen beleggingsadvies en geen aanbeveling om iets te kopen of te verkopen.
